General Information of Binding Target of SBP (BTS) (ID: ST00137)
BTS Name
Programmed cell death protein 1
Synonyms
Protein PD-1; hPD-1; CD antigen CD279
BTS Type
Protein
Gene Name
PDCD1
Organism
Homo sapiens (Human)
Function
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy
UniProt ID
Q15116
UniProt Entry
PDCD1_HUMAN
PFam
PF07686
Gene ID
5133
Sequence
MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTS
ESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGT
YLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGS
LVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVP
CVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL
Sequence Length
288
Synthetic Binding Protein (SBP) Targeting This BTS
SBP Name Highest Status Mechanism Affinity Application Details Ref
DARPin anti-PD-1 DARPin-1 Research Blocker N.A. Ovarian cancer [ICD-11: 2C73.Z]
SBP Info
[1]
DARPin anti-PD-1 DARPin-2 Research Blocker N.A. Ovarian cancer [ICD-11: 2C73.Z]
SBP Info
[1]
DART MGD-019 Phase I Inhibitor N.A. Solid tumour/cancer [ICD-11: 2A00-2F9Z]
SBP Info
[2]
DART Tebotelimab Phase III Inhibitor N.A. Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Heme Malignancies
SBP Info
[2]
Diabody anti-c-Met/PD-1 Diabody-mp Research inhibitor Kd: 0.63 nM Tumors [ICD-11: XH1N44]
SBP Info
[3]
Diabody anti-c-Met/PD-1 Diabody-pm Research inhibitor Kd: 32.48 nM Tumors [ICD-11: XH1N44]
SBP Info
[3]
Diabody anti-VEGF x anti-PD-1 Research Inhibitor Kd: 25.1 nM Tumors [ICD-11: XH1N44]
SBP Info
[4], [5]
Miniprotein anti-PD-1 DBL2_03 Research binder Kd: 4200 nM Research tool
SBP Info
[6]
Miniprotein anti-PD-1 DBL2_04 Research binder N.A. Research tool
SBP Info
[6]
Miniprotein anti-PD-1 DBP13_01 Research binder N.A. Research tool
SBP Info
[6]
References
1 Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin? Proteins. J Immunol Res. 2020 Aug 4;2020:7375947.
2 MacroGenics. Product Development Pipeline. 2021.
3 Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy. Oncoimmunology. 2021 Jul 21;10(1):1914954.
4 Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo. Int J Mol Sci. 2018 Sep 25;19(10):2900.
5 Isolation and characterization of human anti-VEGF165 monoclonal antibody with anti-tumor efficacy from transgenic mice expressing human immunoglobulin loci. Cancer Lett. 2009 Jan 8;273(1):28-34.
6 De novo design of protein interactions with learned surface fingerprints